Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.

Abstract The ability of steroid ligands to inactivate the human mineralocorticoid receptor (MR WT ) has been shown to be due to their inability to contact Asn770, a residue of the H3 helix involved in stabilizing contacts with the H11–H12 loop region. However, all steroid ligands that display antagonist properties when bound to MR WT , have been shown to activate a mutant receptor (MR L810 ) associated with a severe form of hypertension. Biochemical studies revealed that S810L mutation induces a change in the receptor conformation and increases the steroid–receptor complexes stability. From a three-dimensional model of the MR ligand-binding domain, it is likely that the S810L mutation causes a steric hindrance between the side chains of Leu810 (H5) and Gln776 (H3) that provokes a bending of the H3 helix. As a consequence, the positioning of MR WT antagonists within the ligand-binding cavity is modified in such a way that they can activate the mutant MR L810 . The results from biochemical studies also revealed that 5α-pregnan-20-one, 4,9-androstadiene-3,17-dione and RU486, unable to bind MR WT , acted as potent MR L810 antagonists.